JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $78 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating for Cytokinetics (NASDAQ:CYTK) and maintained a price target of $78.
September 04, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Cytokinetics, maintaining a price target of $78, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and maintenance of a $78 price target by JMP Securities suggests positive sentiment and confidence in Cytokinetics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100